Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $13,552.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 2,800 shares of the stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $4.84, for a total transaction of $13,552.00. Following the sale, the insider directly owned 278,652 shares in the company, valued at approximately $1,348,675.68. This represents a 0.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Philippe Menu also recently made the following trade(s):

• On Thursday, April 9th, Philippe Menu sold 1,931 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total transaction of $9,152.94.
• On Tuesday, April 7th, Philippe Menu sold 2,400 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total transaction of $11,688.00.
• On Monday, April 6th, Philippe Menu sold 2,700 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total transaction of $13,095.00.
• On Thursday, March 19th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total transaction of $2,912.32.

SOPHiA GENETICS Price Performance

Shares of NASDAQ SOPH opened at $4.70 on Monday. The firm has a market capitalization of $321.90 million, a PE ratio of -9.22 and a beta of 1.04. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01. SOPHiA GENETICS SA has a 1 year low of $2.58 and a 1 year high of $5.70. The firm’s 50-day moving average is $4.75 and its 200-day moving average is $4.70.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.08). The business had revenue of $21.71 million during the quarter, compared to the consensus estimate of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. Equities analysts expect that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. BTIG Research reaffirmed a “buy” rating and issued a $7.00 target price on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Finally, Guggenheim raised their target price on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.00.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Large institutional accumulation — UBS, Akre and several other funds materially increased positions in recent quarters, signaling conviction from some large investors which could provide demand support for the stock.
• Positive Sentiment: Analyst upside — Guggenheim and BTIG have issued Buy ratings and target prices around $7, above the current trading level, giving the stock upside on positive research momentum.
• Neutral Sentiment: Multiple executives sold small blocks of shares under pre‑arranged Rule 10b5‑1 plans to cover tax withholding associated with vested awards; these are routine and reduce the informational signal from insider sales. Representative SEC filing for CEO sales. CEO Form 4
• Neutral Sentiment: Additional planned sales by other insiders (CFO, President, CTO and others) were disclosed; most trades are modest relative to executive holdings and were executed under 10b5‑1 plans — still worth monitoring for short‑term supply impact. Example coverage of a recent insider sale. InsiderTrades article
• Negative Sentiment: Short interest increased ~20% in late March to ~255k shares (≈0.4% of float), raising potential downward pressure and the possibility of elevated volatility if shorts add to positions or cover into thin trading days.
• Negative Sentiment: Recent fundamentals remain challenged — SOPH reported an EPS miss in early March and continues to show negative margins and ROE; analysts still model negative EPS for the year, which keeps valuation sensitivity high.

Institutional Trading of SOPHiA GENETICS

A number of hedge funds have recently modified their holdings of SOPH. Savvy Advisors Inc. acquired a new stake in shares of SOPHiA GENETICS in the 3rd quarter valued at approximately $48,000. Squarepoint Ops LLC acquired a new stake in shares of SOPHiA GENETICS in the 3rd quarter valued at approximately $49,000. Perkins Capital Management Inc. acquired a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at approximately $49,000. Quadrature Capital Ltd acquired a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at approximately $54,000. Finally, XTX Topco Ltd acquired a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at approximately $55,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.